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Simple Summary: The incidence of cutaneous melanoma is increasing worldwide, currently respon-
sible for 287,723 new cases and 60,712 deaths per year (GLOBOCAN, IARC, WHO). It should be
also highlighted that some less frequent subtypes of melanomas—i.e., acral, uveal, and mucous
melanoma—are responsible for significant morbidity associated with metastasis, responding typi-
cally worse to newer therapies. Therefore, new biomarkers are needed to improve the prognosis in
individual patients. In this sense, the present study showed that CCND1/cyclin D1 upregulation
is a common molecular oncogenic alteration in melanomas that probably favors the growth and
expansion on cutaneous primary melanomas. Furthermore, immunohistochemical cyclin D1 over-
expression strongly predicted a higher Breslow thickness, currently considered the most relevant
prognostic factor in individual patients with melanomas. Finally, special attention should be paid to
the CCND1/cyclin D1 complex in mucosal melanomas, whose upregulation was strikingly altered.
Abstract: Our objective was to evaluate the prognostic and clinicopathological significance of cyclin
D1 (CD1) overexpression/CCND1 amplification in melanomas. We searched studies published
before September 2019 (PubMed, Embase, Web of Science, Scopus). We evaluated the quality of
the studies included (QUIPS tool). The impact of CD1 overexpression/CCND1 amplification on
overall survival and relevant clinicopathological characteristic were meta-analyzed. We performed
heterogeneity, sensitivity, small-study effects, and subgroup analyses. Forty-one studies and 3451
patients met inclusion criteria. Qualitative evaluation demonstrated that not all studies were per-
formed with the same rigor, finding the greatest risk of bias in the study confounding domain.
Quantitative evaluation showed that immunohistochemical CD1 overexpression had a statistical
association with Breslow thickness (p = 0.007; OR = 2.09,95% CI = 1.23–3.57), significantly higher
frequency of CCND1/cyclin D1 abnormalities has been observed in the primary tumor compared
to distant metastases (p = 0.004), revealed also by immunohistochemical overexpression of the pro-
tein (p < 0.001; OR = 0.53,95% CI = 0.40–0.71), while the CCND1 gene amplification does not show
association (p = 0.43); while gene amplification, on the contrary, appeared more frequently in distant
metastases (p = 0.04; OR = 1.70,95% CI = 1.01–2.85) and not in the primary tumor. In conclusion,
CCND1/cyclin D1 upregulation is a common molecular oncogenic alteration in melanomas that prob-
ably favors the growth and expansion of the primary tumor. This upregulation is mainly consequence
to the overexpression of the cyclin D1 protein, and not to gene amplification.
Keywords: melanoma; cyclin D1; CCND1; systematic review; meta-analysis
Cancers 2021, 13, 1314. https://doi.org/10.3390/cancers13061314 https://www.mdpi.com/journal/cancers
Cancers 2021, 13, 1314 2 of 21
1. Introduction
The incidence of cutaneous melanoma is currently 287,723 new cases, this tumor being
responsible for 60,712 deaths per year (GLOBOCAN, IARC, WHO) [1]. These figures are
increasing and is expected to continue growing worldwide [2] as a consequence essentially
of excessive exposure to sunlight related to leisure, which undoubtedly will increase the
health investment dedicated to the diagnosis and treatment of this tumor [3]. It should be
also highlighted that some less frequent subtypes of melanomas—i.e., acral, uveal, and
mucous melanomas—are responsible for significant morbidity associated with metastasis,
responding typically worse to newer therapies [4]. Although the use of advanced therapies
based on new drugs approved by the FDA have been applied to treatment since 2011 [5],
all of the aforementioned advises the development of extensive research, which provides
enough scientific evidence especially on new therapeutic targets, with the aim of developing
new drugs specifically aimed toward these new targets that can improve patient prognosis.
Cyclin D1, encoded by the CCND1 gene located on chromosome band 11q13, pro-
motes cell cycle progression during the G1-S phase [6]. Since some years, it has been known
that CCND1 can act as a relevant oncogene in some types of tumors, having established in
addition to its pro-proliferative activity several others emerging oncogenic functions includ-
ing increase of cell migration capacity, inhibition of cell differentiation, inhibition of DNA
repair, and involvement in mitochondrial metabolism [7]. The canonical CCND1/cyclin D1
general role—i.e., sustaining cell proliferation—has also been also shown in in vitro [8–10]
and in vivo [11–13] recent studies in melanoma. Although no studies have been designed
to provide direct evidence of the other emerging functions of cyclin D1 in melanoma,
some studies have observed an increase in cell migration after the activation of upstream
regulators of cyclin D1 in melanomas [14,15]. Finally, the pro-proliferative activity of cyclin
D1 has also been shown in melanomas in population-based studies, verified through the
evaluation of the ki-67 proliferative index [16–18].
Gene amplification is the main mechanism of CCND1/cyclin D1 upregulation in
cancer [19–21], although in melanoma, other genetic alterations seem to be also involved in
the dysregulation of the cyclin D1 function, including mutations, polymorphisms, chro-
mosomal translocations, and the activation of several oncogenic pathways (MAPK, PI3K,
Wnt, NF-κβ) [22]. CCND1/cyclin D1 upregulation has been reported to be associated
with reduced survival and lack of response to antitumor treatment in melanoma [22–24].
CCND1/cyclin D1 have also been proposed as a candidate therapeutic target, because their
transcription depends on several upstream pathways essential for tumor development.
Cyclin D1 could be targeted in melanoma in several ways—extensively reviewed in Yadav
et al. (2015) and González-Ruiz et al. (2020)—by inhibition of chromosome band 11q13
and/or CCND1; by direct inhibition of cyclin D1; by CDK inhibition, acting upstream in
melanoma-related pathways involving cyclin D1; or combining agents that act against
cyclin D1 with other antitumor drugs. This latter therapy has been proposed as the most
promising option [22], particulary the combination of BRaf inhibitory drugs with cyclin
D1-CDK4/6 inhibitory agents (i.e., abemaciclib [LY2835219], palbociclib [PD0332991], or
ribociclib [LEE011]), with some ongoing or completed phase II trials and clinical trials
(NCT02202200, NCT02159066, NCT01820364) [13,25,26]. CCND1/cyclin D1 upregulation
could also have specific importance in melanoma context as in the prediction of clinico-
pathological (e.g., higher Breslow thickness [27] or clinical stage [28]) and/or prognostic
(e.g., poor survival [29]) outcomes. Although published data support an empirical assump-
tion about the direction of the effect, and our hypothesis is that CCND1/cyclin D1 could
behave as an useful biomarker, some primary-level studies have reported disparities or a
lack of statistical significance [30,31].
With this background, the present paper aims to qualitatively and quantitatively
evaluate for first time, through a systematic review and comprehensive meta-analysis,
the available scientific evidence on the clinicopathological and prognostic implications of
CCND1 gene amplification and cyclin D1 immunohistochemical protein overexpression
in melanomas.
Cancers 2021, 13, 1314 3 of 21
2. Materials and Methods
The present systematic review and meta-analysis complied with PRISMA guide-
lines [32] and closely followed the criteria of Cochrane Prognosis Methods Group [33],
Cochrane Handbook for Systematic Reviews of Interventions [34], and Centre for Reviews
and Dissemination (CRD)’s guidance for undertaking reviews in healthcare [35].
2.1. Protocol
In order to minimize the risk of bias and improve the transparency, precision, and
integrity of our systematic review and meta-analysis, a protocol on its methodology was
registered a protocol in PROSPERO international prospective register of systematic re-
views (www.crd.york.ac.uk/PROSPERO (accessed on 15 March 2021), registration number
CRD42020153664; a copy of the protocol was included in the Supplementary Materials,
pp. 60–64) [36]. The protocol adhered to PRISMA-P guidelines in order to ensure a rigorous
approach [37].
2.2. Search Strategy
We searched PubMed, Embase, Web of Science, and Scopus databases for studies
published before the search date (upper limit = September 2019), with no lower date limit.
Searches were conducted by combining thesaurus terms used by the databases (e.g., MeSH
and EMTREE) with free terms (the syntax adapted to each database can be found in the
Supplementary Materials, Table S1, p. 5), and constructed to maximize sensitivity. We also
manually screened the reference lists of retrieved studies for additional relevant studies. All
references were managed using Mendeley v.1.19.3 (Elsevier. Amsterdam, The Netherlands);
duplicate references were eliminated using this software.
2.3. Selection Criteria
Study eligibility criteria were applied independently by two authors (LGR and PRG).
Any discrepancies were resolved by consensus with the senior author (MAGM).
Inclusion criteria: (1) Original research studies published in English. (2) Evaluation of
CCND1 amplification or cyclin D1 overexpression in human cutaneous, uveal or mucosal
melanomas. (3) Analysis of the association of CCND1 and/or cyclin D1 upregulation with
clinicopathological and/or prognostic variables. Given the lack of international consensus
standards to define survival endpoints, we included studies that used the direct designation
of the terms overall survival (OS) or disease-free survival (DFS). OS was defined as the time
elapsed from date of diagnosis/surgery to date of death by any cause. DFS was defined
as the time elapsed from surgery to the detection of locoregional or distant recurrence or
to death without recurrence. Other terms defined in the original studies as in the present
article or compatible with our definitions (e.g., relapse-free survival) were also accepted.
(4) The author names, affiliations, recruitment periods, and setting were examined to
determine whether studies were conducted in the same study population. In such cases,
we included the most recent study or that which published more complete data.
Exclusion criteria: (1) Retractions, reviews, meta-analyses, case reports, editorials,
letters, abstracts of scientific meetings, personal opinions or comments, book chapters,
and any study in a language other than English; (2) Studies with no melanoma cases; (3)
Reports of in vitro or animal experiments; (4) Evaluations of CCND1 gene alterations other
than gene amplification (e.g., polymorphisms) and studies of chromosome band 11q13
that do not specifically discriminate the CCND1 gene; (5) No analysis of the relationship
of upregulation with clinicopathological or prognostic variables; (6) Insufficient data
for the estimation of odds ratios (ORs) for clinicopathological variables and, in studies
only reporting time-to-event variables (OS/DFS), the absence of hazards ratios (HRs)
with 95% confidence intervals (CIs) or the lack of adequate data for their calculation by
survival analysis.
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We first screened the titles and abstracts of retrieved articles to select those that
appeared to meet the review eligibility criteria. In a second phase, we examined the full
texts of the selected articles and removed any that did not fulfill these criteria.
2.4. Data Extraction
Two authors (LGR and PRG) independently extracted data from the articles selected
for full text study in a standardized fashion using an Excel data collection template (Excel
v.2015, Microsoft. Redmond, WA, USA). The extracted data were then reviewed by the
senior author (MAGM). Discrepancies were solved by consensus. Data were gathered on:
first author, year of publication, country and continent, sample size, alteration under study
(CCND1 amplification and/or cyclin D1 overexpression), type of melanomas, location,
recruitment and follow-up periods, methodology, and the upregulation frequency. Further-
more, in immunohistochemical studies, information was also recorded on the cutoff point,
anti-cyclin D1 antibody, and intracellular immunopositivity pattern (nuclear/cytoplasmic).
2.5. Evaluation of Quality and Risk of Bias
Two authors (LGR and PRG) evaluated the quality of studies and the risk of bias
using the Quality in Prognosis Studies (QUIPS) tool of the Cochrane Prognosis Methods
Group [38], which explores six main potential bias domains: (1) Study participation, (2)
Study attrition, (3) Prognostic factor measurement, (4) Outcome measurement, (5) Study
confounding, and (6) Statistical analysis and reporting [39]. The potential risk of bias was
evaluated as low, moderate, or high for each domain. Discrepancies were resolved with a
senior author (MAGM).
2.6. Statistical Analysis
CCND1 amplification was considered “positive” or “negative” according to the
methodology adopted in each study. Cyclin D1 expression was considered “high” or
“low” according to the cutoff values applied in each study. We used hazards ratio (HR)
with 95% confidence intervals (CIs) to estimate the impact of CCND1/cyclin D1 upregu-
lation on time-to-event variables (OS and DFS). When reported, HRs and 95% CIs were
directly extracted from the original articles. If HRs were not explicitly provided by the
authors, they were calculated using the methods described in Parmar et al. [40] and Tierney
et al. [41]. When HRs were evaluated in both univariable and multivariable models, we
used the data from the multivariable model, which reflect a greater adjustment for poten-
tially confounding variables [42]. When data were only depicted in Kaplan–Meier curves
or HRs and 95% CIs were only expressed graphically, data were measured and extracted
using Engauge Digitizer 4.1 (open-source digitizing software developed by M. Mitchell).
In meta-analyses, HRs and 95% CIs were pooled using a random-effect model (REM, Der
Simonian and Laird (D-L) method), because logic dictates the presence of a considerable
degree of between-study heterogeneity.
Clinicopathological parameters were meta-analyzed using odds ratios (OR) with 95%
CIs. As the authors only reported raw data, this information was collected and re-expressed
as ORs, which were pooled by Mantel–Haenszel’s method, using a fixed-effect model. A
random-effects model using the inverse variance method was not considered a priori,
because when data are sparse, heterogeneity is uncommon and the Mantel–Haenszel
weighting method has been shown to have better statistical properties [43]. Peto’s method
was not considered because many studies presented unbalanced arms.
Finally, meta-analyses were carried out trying to estimate the overall frequency of
cyclin D1/CCND1 expression and amplification levels for the different types of melanoma
under investigation (i.e., cutaneous [nodular, superficial spreading, lentigo malignant, and
acral melanoma], uveal and mucosal). To achieve this, pooled proportions (PP) with their
corresponding 95% CIs were estimated. Proportions in individual studies were calculated
by extracting raw numerators (number of cases with cyclin D1 high expression or CCND1
positive amplification) and denominators (total number of melanoma cases). The 95%
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CIs were constructed based on the score-test statistic [44].The influence of studies with
extremely small or high values (0 or 100, or close to 0 or 100) was minimized by using
Freeman–Tukey double-arcsine transformation to stabilize the variance of proportions [45].
PP were estimated using a REM (D-L method).
In all conducted meta-analyses, forest plots were constructed to graphically repre-
sent the overall effect and for its subsequent analysis (a p-value < 0.05 was considered
statistically significant) [46]. Heterogeneity between studies was checked using the χ2
based Cochran’s Q test. Given the low statistical power of this test, p < 0.1 was considered
significant. We also used Higgins I2 statistic to quantify the percentage heterogeneity,
considering values of 25, 50, and 75% to indicate low, moderate, and high heterogeneity,
respectively [46,47]. Additionally, subgroup analyses—preplanned in our protocol—were
performed (stratifying by CCND1/cyclin D1 upregulation, geographic area, cut-off value,
and immunostaining pattern) to identify potential sources of heterogeneity and to explore
the relationship between the meta-analyzed parameters in these subgroups. Sensitivity
analyses were additionally carried out to test the reliability of combined results, evaluating
the influence of each individual study on the final estimations for each meta-analysis
performed [48]. For this, the “leave-one-out” method was used (i.e., the meta-analyses
were repeated sequentially, omitting one study at a time). Funnel plots were constructed
and the Egger regression test (pEgger < 0.1) was applied to evaluate small-study effects,
such as publication bias [49,50]. Stata version 14.1 (Stata Corporation, College Station, TX,
USA) was employed for all tests, using commands written by the user.
3. Results
3.1. Literature Search
The flow diagram in Figure 1 depicts search, study selection process, and the results
obtained. A total of 3175 records published before September 2019 were retrieved from
PubMed (n = 492), Embase (n = 1110), Web of Science (n = 728), and Scopus (n = 845).
One additional record was also identified handsearching the references lists of the studies
included. After duplicates removal, 1428 studies were considered potentially eligible.
After the titles and abstracts screening, 109 records were selected for full-text evaluation,
of which 68 did not meet all inclusion criteria, leaving a final sample of 41 studies (the
references of the studies included in the systematic review and meta-analysis are listed in
the Supplementary Materials, pp. 56–59).
3.2. Study Characteristics
Table 1 summarizes the main characteristics of the 41 studies analyzing the prognos-
tic and clinicopathological implications of CCND1/cyclin D1 upregulation in 3451 melanomas.
Cyclin D1 protein overexpression was assessed by 21 studies in 1473 melanomas (range: 7–245);
CCND1 gene amplification was also analyzed by 22 studies in 2096 melanomas (range: 6–
514). Two studies analyzed both CCND1/cyclin D1 alterations (118 melanomas) [24,51]. The
studies were conducted in 6 continents (Europe, 17 studies/1727 melanomas; North America,
12 studies/498 melanomas; Asia, 5 studies/893 melanomas; South and Central America,
3 studies/110 melanomas; and two global multicentric studies, 60 melanomas) and 17 coun-
tries (Australia, 2 studies; Brazil, 1 study; China, 3 studies; France, 1 study; Germany, 4 studies;
Greece, 1 study; Hungary, 2 studies; Italy, 3 studies; Japan, 2 studies; global multicentric,
2 studies (Australia-USA, and Germany-Japan-South Korea-USA); South and Central America
multicentric, 2 studies (Bolivia-Brazil and Brazil-Guatemala-Mexico-Peru); Norway, 2 studies;
Spain, 3 studies; Switzerland, 1 study; and USA, 12 studies). Table S2 (Supplementary Materi-
als, pp. 6–12) exhibits in more detail the characteristics (type of melanoma, affected sites, and
methods) gathered from each study.
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Figure 1. Flow diagram of the identification and selection of relevant studies, analyzing the prognostic
and clinicopathological significance of CCND1/cyclin D1 alterations in melanomas.
Table 1. Summarizes the main ch racter stics of reviewed studies. Table S2 ( n Suppleme tary Mate-
rials, pp. 6–12) exhibits in detail the characteristics (type of melanoma, affected sites, and methods)
of each study. * —Two studies analyzed both CCND1/cyclin D1 alterations (118 melanomas).
Total 41 Studies
Year of publication 1999–2019
Number of melanomas analyzed
Total 3451
Sample size, range 6–514
Cyclin D1 protein overexpression *
Tot l 21 studies (1473 melanoma )
Sample size, range 7–245
CCND1 gene amplification *
Total 22 studies (2096 melanomas)
Sample size, range 6–514
Geographical region
Europe 17 studies (1727 melanomas)
No th America 12 studies (498 melanomas)
Asia 5 studies (893 melanomas)
South and Central America 3 studies (110 melanomas)
Australia 2 studies (163 melanomas)
Global multicentric 2 studies (60 melanomas)
Total 6 continents, 17 countries
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3.3. Qualitative Evaluation
Qualitative analysis was conducted using the QUIPS tool, which evaluates potential
sources of bias in six domains (Figure 2).
Figure 2. Evaluation of the risk of bias using the Quality in Prognosis Studies (QUIPS) tool (the
references cited in this figure are listed in Supplementary Materials).
Study participation. The studies had a high (53.66%), moderate (29.27%), or low
(17.07%) risk of bias (Figure 2), related to the lack of reporting relevant data (type of
melanomas, affected site, age, sex, recruitment period, and/or relevant parameters with
prognostic implications, e.g., Breslow thickness).
Study attrition. The studies evaluated had a high (4.88%), moderate (9.76%), or low
(85.36%) risk of bias (Figure 2), mainly due to the lack of information on the follow-up
period. The attempt to gather information on patients lost in the follow up period was not
described by the studies.
Prognostic factor measurement. The studies had a high (24.39%), moderate (9.76%),
or low (65.85%) risk of bias (Figure 2). The biases encountered were due to insufficient
information on the techniques used to measure the levels of amplification or overexpression
(e.g., laboratory methods or scoring system) or questionable methodologies (e.g., use of
inappropriate cutoff points). In immunohistochemical studies, insufficient information
about anti-cyclin D1 antibodies, immunopositivity pattern (nuclear or cytoplasmic), or the
failure to report images of the technique.
Outcome measurement. The studies had a high (34.15%), moderate (12.19%), or low
(53.66%) risk of bias (Figure 2), due to failure to define the survival outcomes evaluated
(this is essential, due to the lack of international consensus on survival endpoints). Further-
more, the reporting of N and M status in combination, or an inadequate measurement of
prognostic parameters (e.g., optimized cut-off points for clinicopathological variables to
obtain significant p-values).
Study confounding. The studies had a high (95.24%) or moderate (4.76%) risk of bias
(Figure 2), due to the failure considering potential confounders. None of the studies defined
a priori the confounding factors under evaluation or a posteriori discussed potentially
candidate factors or the biological principles by which they might distort the impact of
CCND1/cyclin D1 upregulation on study parameters.
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Statistical analysis and reporting. The studies had a high (65.86%), moderate (17.07%),
or low (17.07%) risk of bias (Figure 2) due to selective outcome reporting, lack of essen-
tial information in survival analysis (i.e., Kaplan–Meier courves or hazard ratios with
confidence intervals), suspected data errors, or an inappropriate statistical analysis.
4. Quantitative Evaluation (Meta-Analysis)
4.1. Association between CCND1/Cyclin D1 Upregulation and Cutaneous Melanoma
4.1.1. Upregulation Frequency
Upregulation was a frequent phenomenon in acral melanomas (overexpression:
PP = 62.07%, 95% CI = 31.17–89.27; amplification: PP = 25.06%, 95% CI = 15.80–35.44),
and less frequent—although also present—in nodular (overexpression: PP = 13.69%, 95%
CI = 2.33–29.67; amplification: PP = 22.66%, 95% CI = 3.65–48.29), superficial spread-
ing (overexpression: PP = 36.72%, 95% CI = 17.57–57.90; amplification: PP = 15.79%,
95% CI = 3.44–32.85), and lentigo malignant melanomas (overexpression: PP = 52.24%,
95% CI = 33.36–70.82; amplification: PP = 16.16%, 95% CI = 2.53–35.62) (Table 2, Fig-
ures S1–S4, Supplementary Materials, pp. 13–16). Although considerable degrees of
heterogeneity were reached for the alterations analyzed together, the subgroups were
more homogeneous after applying the stratification by overexpression and amplification.
4.1.2. Overall Survival (OS)
A non-significant association was found for both cyclin D1 overexpression (HR = 1.00,
95% CI = 0.64–1.58, p = 0.99) and CCND1 amplification (HR = 1.32, 95% CI = 0.81–1.52,
p = 0.11) (Table 2, Figure S5, Supplementary Materials, p. 17). There was no evidence
of heterogeneity among studies (phet = 0.30, I2 = 16.7%). In the stratified analyses by
geographic area and immunohistochemical pattern, the results did not vary significantly
among the subgroups under analysis (Table 2, Figures S6 and S7, Supplementary Materials,
pp. 18, 19). Additional planned analyses (by anti-cyclin D1 antibody and cutoff point)
were not possible for any parameter due to the heterogeneous and small amount of data
reported by the studies.
4.1.3. Disease-Free Survival (DFS)
CCND1/cyclin D1 upregulation was not significantly associated with poor DFS
(HR = 1.45, 95% CI = 0.60–3.51, p = 0.41) (Table 2, Figure S8, Supplementary Materials, p. 20).
As only 2 studies were included for this variable, subgroups analyses were not performed.
4.1.4. Breslow Thickness
A significant large effect size (OR = 2.09, 95% CI = 1.23–3.57, p = 0.007) was found
with cyclin D1 overexpression, while this association was not found for gene amplification
(OR = 1.21, 95% CI = 0.75–1.95, p = 0.43) (Table 2, Figure 3). Heterogeneity across studies
was not evident (phet = 0.52, I2 = 0.0%). In the stratified analysis, the European (OR = 1.91,
95% CI = 1.15–3.19, p = 0.01) subgroup maintained the significant association (Table 2,
Figure S9, Supplementary Materials, p. 21).
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Nodular melanoma b 15 219 D-L REM PP = 19.19%(7.12–34.06) - <0.001 70.63 Figure S1, p. 13
Nodular melanoma by
alteration c Figure S1, p. 13
Cyclin D1 overexpression 7 103 D-L REM PP = 13.69%(2.33–29.67) - 0.13 39.69
CCND1 amplification 8 116 D-L REM PP = 22.66%(3.65–48.29) - <0.001 80.92
Superficial spreading
melanoma b
15 553 D-L REM PP = 24.71%(13.29–37.84) - <0.001 86.26 Figure S2, p. 14
Superficial spreading
melanoma by alteration c Figure S2, p. 14
Cyclin D1 overexpression 7 325 D-L REM PP = 36.72%(17.57–57.90) - <0.001 88.53
CCND1 amplification 8 228 D-L REM PP = 15.79%(3.44–32.85) - <0.001 83.30
Lentigo malignant
melanoma b
5 63 D-L REM PP = 34.73%(10.61–63.09) <0.001 76.77 Figure S3, p. 15
Lentigo malignant
melanoma by alteration c - Figure S3, p. 15
Cyclin D1 overexpression 2 29 D-L REM PP = 52.24%(33.36–70.82) - - -
CCND1 amplification 3 34 D-L REM PP = 16.16%(2.53–35.62) - 0.27 23.42
Acral melanoma b 7 98 D-L REM PP = 30.90%(18.27–44.86) - 0.15 36.98 Figure S4, p. 16
Acral melanoma by
alteration c Figure S4, p. 16
Cyclin D1 overexpression 2 13 D-L REM PP = 62.07%(31.17–89.27) - - -
CCND1 amplification 5 85 D-L REM PP = 25.06%(15.80–35.44) - 0.44 0.00
Survival parameters
Overall survival d 7 1022 D-L REM HR = 1.11(0.81–1.52) 0.51 0.30 16.7 Figure S5, p. 17
Overall survival by
alteration e Figure S5, p. 17
Cyclin D1 overexpression 5 399 D-L REM HR = 1.00(0.64–1.58) 0.99 0.26 24.3
CCND1 amplification 2 623 D-L REM HR = 1.32(0.81–1.52) 0.11 - -
Overall survival by
geographic area e Figure S6, p. 18
Asian 2 592 D-L REM HR = 1.30(0.92–1.82) 0.13 - -
Non-Asian 5 430 D-L REM HR = 1.03(0.63–1.69) 0.90 0.23 28.3
Overall survival by IHQ
pattern e Figure S7, p. 19
Nuclear 3 235 D-L REM HR = 0.77(0.50–1.17) 0.22 0.58 0.0
Nuclear and cytoplasmic 1 78 - - - - - -
Not available 1 86 - - - - - -
Clinicopathological
parameters
Disease-free survival d 2 70 D-L REM HR = 1.45(0.60–3.51) 0.41 - - Figure S8, p. 20
Breslow thickness d 16 760 M-H FEM OR = 1.54(1.08–2.20) 0.02 0.52 0.0 Manuscript,
Figure 3Breslow thickness byalteration e
Cyclin D1 overexpression 7 264 M-H FEM OR = 2.09(1.23–3.57) 0.007 0.27 20.4
CCND1 amplification 9 496 M-H FEM OR = 1.21(0.75–1.95) 0.43 0.87 0.0
Breslow thickness by
geographic area e Figure S9, p. 21
Asia 2 120 M-H FEM OR = 1.31(0.63–2.74) 0.47 - -
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Nodular melanoma b 15 219 D-L REM PP = 19.19%(7.12–34.06) - <0.001 70.63 Figure S1, p. 13
Australia 1 143 - - - - - -
Europe 7 355 M-H FEM OR = 1.91(1.15–3.19) 0.01 0.21 28.4
Global multicentric 1 39 - - - - - -
North America 4 41 M-H FEM OR = 1.36(0.31–5.90) 0.68 0.73 0.0
South America 1 62 - - - - - -
Breslow thickness by IHQ
pattern e Figure S10, p. 22
Nuclear 3 89 M-H FEM OR = 1.83(0.72–4.61) 0.20 0.06 65.3
Nuclear and cytoplasmic 1 78 - - - - - -
Not available 3 97 M-H FEM OR = 2.41(0.98–5.90) 0.06 0.41 0.0
Ulceration d 4 759 M-H FEM OR = 0.99(0.70–1.42) 0.97 0.40 0.0 Figure S11, p. 23
N Status d 2 16 M-H FEM OR = 0.77(0.06–9.14) 0.83 - - Figure S12, p. 24
M Status d 2 34 M-H FEM OR = 0.86(0.15–5.02) 0.87 - - Figure S13, p. 25
Clinical Stage d 3 585 M-H FEM OR = 1.13(0.78–1.66) 0.51 0.03 70.5 Figure S14, p. 26
Mitotic rate d 2 117 M-H FEM OR = 1.66(0.72–3.84) 0.23 0.71 0.0 Figure S15, p. 27
Clark levels d 7 195 M-H FEM OR = 1.10(0.59–2.06) 0.76 0.34 12.1 Figure S16, p. 28
Type (nodular vs.
SSM/LMM/AM) d
13 646 M-H FEM OR = 0.84(0.52–1.35) 0.47 0.14 30.4 Figure S17, p. 29
Type by alteration e Figure S17, p. 29
Cyclin D1 overexpression 6 337 M-H FEM OR = 0.53(0.26–1.08) 0.08 0.30 17.1
CCND1 amplification 7 309 M-H FEM OR = 1.29(0.66–2.51) 0.45 0.23 26.4
Type by geographic area e Figure S18, p. 30
Australia 1 9 - - - - - -
Europe 4 275 M-H FEM OR = 1.54(0.80–2.97) 0.19 0.52 0.0
Global multicentric 1 33 - - - - - -
North America 6 268 M-H FEM OR = 0.34(0.14–0.84) 0.02 0.08 50.1
South America 1 61 - - - - - -
Type by IHQ pattern e Figure S19, p. 31
Nuclear 5 304 M-H FEM OR = 0.54(0.26–1.11) 0.09 0.20 33.5
Not available 1 33 - - - - - -
Lymph node metastasis vs.
primary tissue d
2 184 M-H FEM OR = 1.07(0.43–2.68) 0.88 0.21 35.7 Figure S20, p. 32
Distance metastasis vs.
primary tissue d 16 1651 M-H FEM
OR = 0.70
(0.55–0.89) 0.004 <0.001 68.5 Figure S21, p. 33
By alteration e Figure S21, p. 33
Cyclin D1 overexpression 9 987 M-H FEM OR = 0.53(0.40–0.71) <0.001 <0.001 71.8
CCND1 amplification 7 664 M-H FEM OR = 1.70(1.01–2.85) 0.04 0.16 35.5
By geographic area e Figure S22, p. 34
Asia 2 122 M-H FEM OR = 0.42(0.18–1.00) 0.05 - -
Australia 1 20 - - - - - -
Europe 9 1237 M-H FEM OR = 0.73(0.55–0.97) 0.03 <0.001 73.0
North America 4 272 M-H FEM OR = 0.72(0.39–1.34) 0.30 0.001 82.2
By IHQ pattern e Figure S23, p. 35
Nuclear 7 826 M-H FEM OR = 0.56(0.41–0.76) <0.001 <0.001 78.3
Nuclear and cytoplasmic 1 101 - - - - - -
Not available 1 60 - - - - - -
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Uveal melanoma b 3 197 D-L REM PP = 14.42%(0.00–46.91) - <0.001 95.91 Figure S24, p. 36
Survival parameters
OS 0 0 - - - - - - -
DFS d 1 45 - - - - - - -
Clinicopathological
parameters
Thickness 1 32 - - - - - - -
Distance metastasis 1 82 - - - - - - -
Sclera infiltration 1 45 - - - - - - -
Largest basal dimensiond 2 77 M-H FEM OR = 2.78(0.950–8.16) 0.06 - - Figure S25, p. 37
Pathology (epithelioid vs.
spindle/mixed) d




Mucosal melanoma b 12 356 D-L REM PP = 42.33%(27.24–58.12) - <0.001 86.76 Figure S27, p. 39
Mucosal melanoma by
alteration c Figure S27, p. 39
Cyclin D1 overexpression 4 94 D-L REM PP = 75.69%(55.48–91.63) - 0.01 74.22
CCND1 amplification 8 262 D-L REM PP = 25.08%(17.29–33.66) - 0.09 42.72
Mucosal melanoma by
anatomical site c Figure S28, p. 40
Ano-rectal 1 45 - - - - - -
Conjunctival 1 6 - - - - - -
Head and neck mixed 1 94 - - - - - -
Esophageal 2 29 D-L REM PP = 13.51%(2.47–29.52) - - -
Genitourinary 1 55 - - - - - -
Oral cavity 2 46 D-L REM PP = 80.05%(66.67–90.94) - - -
Sinonasal 4 81 D-L REM PP = 41.47%(14.11–71.73) - <0.001 86.1
Survival parameters
OS 0 0 - - - - - - -
DFS 0 0 - - - - - - -
Recurrence d 2 41 M-H FEM OR = 0.90(0.18–4.38) 0.89 - - Figure S29, p. 41
Clinicopathological
parameters
Thickness d 4 241 M-H FEM OR = 1.19(0.67–2.11) 0.56 0.17 39.6 Figure S30, p. 42
N Status 0 0 - - - - - - -
M Status d 2 40 M-H FEM OR = 1.95(0.21–18.30) 0.56 0.77 0.0 Figure S31, p. 43
Necrosis d 3 65 M-H FEM OR = 0.90(0.30–2.70) 0.85 0.70 0.0 Figure S32, p. 44
Abbreviations: Stat., statistical; Wt, method of weighting; ES, estimation; CI, confidence intervals; REM, random-effects model; FEM,
fixed-effects model; D-L, DerSimonian and Laird method; M-H, Mantel-Haenszel method; PP, pooled proportion; HR, hazard ratio; OR,
odds ratio. a- More information in the appendix; b- Proportion meta-analyses; c- Proportion meta-analyses (Subgroup analyses); d-
Prognosis meta-analyses; e- Prognosis meta-analyses (Subgroup analyses).
4.1.5. Distance Metastatic vs. Primary Tissue
A strong significant association was found between cyclin D1 and its overexpres-
sion in primary tissues (OR = 0.53, 95% CI = 0.40–0.71, p < 0.001). On the other hand, a
weaker association was found for CCND1 amplification in metastatic tissue (OR = 1.70,
95% CI = 1.01–2.85, p = 0.04). Although a considerable heterogeneity degree was observed
(phet < 0.001; I2 = 68.5%), the subgroups were more homogeneous after being stratified
by alteration, and heterogeneity lost its significance for gene amplification (phet = 0.16,
I2 = 35.5%) (Table 2, Figure S21, Supplementary Materials, p. 33). In the stratified anal-
yses, the European (OR = 0.73, 95% CI = 0.55–0.97, p = 0.03) subgroup and the nuclear
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immunopositive pattern (OR = 0.56, 95% CI = 0.41–0.76, p < 0.001) strongly maintained
their significant associations with primary tissues upregulation (Table 2, Figures S22 and
S23, Supplementary Materials, pp. 33, 34).
Figure 3. Forest plot graphically representing the association between CCND1/cyclin D1 alterations
and Breslow thickness in cutaneous melanomas. OR, odds ratio; CI, confidence intervals. Fixed-effect
model (Mantel–Haenszel method) pooling odds ratios (the references cited in this figure are listed in
Supplementary Materials).
4.1.6. Additional Clinicopathological Variables
Neither cyclin D1 overexpression nor CCND1 amplification were significantly associ-
ated with the other variables analyzed (ulceration, N and M status, clinical stage, mitotic
rate, Clark levels and type of melanoma; Table 2, Figures S11–S19, Supplementary Materi-
als, pp. 23–31). A considerable significant degree of heterogeneity was only reached by
clinical stage (phet = 0.03, I2 = 70.5%). Due to the low number of studies included in these
variables, subgroups analyses were only performed for type of melanoma. Nevertheless,
relevant subpopulations harboring higher levels of cyclin D1 or CCND1 amplification were
not found (Table 2, Figures S17–S19, Supplementary Materials, pp. 29–31).
4.2. Association between CCND1/Cyclin D1 Upregulation and Uveal Melanoma
Upregulation frequency. Upregulation was very inconsistent across studies in uveal
melanomas (PP = 14.42%, 95% CI = 0.00–46.91; phet < 0.001, I2 = 95.91%) (Table 2, Figure S24,
Supplementary Materials, p. 36). Due to the low number of studies included (n = 3), hetero-
geneity sources—performing subgroups analyses—could not be investigated or explained.
Prognostic and clinicopathological variables. Meta-analyses could only be performed
for the variables largest basal dimension (N.S) and pathologic cell type, in which the epithe-
lioid shaped cells showed a significant and imprecise association (very large magnitude
of effect) with CCND1/cyclin D1 upregulation (OR = 4.59, 95% CI = 1.47–14.36, p = 0.009)
(Table 2, Figures S25 and S26, Supplementary Materials, pp. 37, 38).
4.3. Association between CCND1/Cyclin D1 Upregulation and Mucosal Melanoma
4.3.1. Upregulation Frequency
Upregulation was a very frequent phenomenon in mucosal melanomas (overexpres-
sion: PP = 75.69%, 95% CI = 55.48–91.63; amplification: PP = 25.08%, 95% CI = 17.29–33.66),
and the subgroups of melanomas arising in the oral cavity showed the highest prevalence
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of the present meta-analysis (PP = 80.05%, 95% CI = 66.67–90.94) (Table 2, Figures S27
and S28, Supplementary Materials, pp. 39, 40). These frequencies were very inconsistent
across studies and responsible sources of heterogeneity could not be detected (phet < 0.001,
I2 = 86.76%).
4.3.2. Prognostic and Clinicopathological Variables
Meta-analyses could only be performed for tumor thickness, status M, and necrosis,
but none of the variables was statistically associated with CCND1/cyclin D1 upregulation
(Table 2, Figures S29–S32, Supplementary Materials, pp. 41–44).
4.4. Quantitative Evaluation (Secondary Analyses)
4.4.1. Sensitivity Analysis
In general, the overall results did not substantially vary after the sequential repetition
of meta-analyses, omitting one study each turn (“leave-one-out” method) (Tables S3–S8,
Supplementary Materials, pp. 50–55). Therefore, these sensitivity analyses series suggest
that the precedent pooled estimations are robust and do not depend on the influence of a
particular individual study.
4.4.2. Analysis of Small-Study Effects
Visual inspection of the asymmetry of funnel plots and of the statistical tests conducted
for the same purpose confirmed the absence of small-study effects on the variables OS
(pEgger = 0.82), Breslow thickness (pEgger = 0.56; Figure 4), distance metastatic vs. primary
tissue (pEgger = 0.17), type of melanoma (pEgger = 0.23), ulceration (pEgger = 0.37), and Clark
levels (pEgger = 0.43) in cutaneous melanomas (Figures S33–S37, Supplementary Materials,
pp. 45–49), for which biases (e.g., publication bias) can be ruled out. The variables DFS, N,
and M status, ganglionar metastatic vs. primary tissue, clinical stage and mitotic rate in
cutaneous melanomas (idem for uveal and mucosal) did not meet the conditions for the
statistical analysis of small-study effects, since a low number of studies were included in
their respective meta-analyses.
Figure 4. A funnel plot of estimated logOR against its standard error, graphically representing
the analysis of “small-study” effects on Breslow thickness. The black vertical line corresponds to
the pooled estimated prevalence. The two diagonal intermittent lines represent the pseudo-95%
confidence interval. The purple circles represent the published studies. The blue line represents the
fitted line corresponding to Egger’s regression test (pEgger = 0.56) for funnel-plot asymmetry. SE,
standard error; OR, odds ratio.
5. Discussion
This systematic review and meta-analysis of 41 studies and 3451 patients, shows
CCND1/cyclin D1 upregulation as a common oncogenic alteration in cutaneous, mucous,
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and uveal melanomas, and we carry out a comparative study of the alterations of this onco-
gene and its product in these different types of melanomas under the hypothesis that per-
haps the upregulation of CCND1/cyclin D1 may be different in these types of melanomas
and to some extent justify their different clinical behavior and prognosis. In cutaneous
melanomas, the highest frequency was observed in lentigo malignant melanoma (37.73%
of cases) followed by acral melanoma, superficial spreading melanoma, and nodular
melanoma (30.90%, 24.71%, and 19.19%, respectively). In uveal melanomas, CCND1/cyclin
D1 upregulation is observed in 14.41% of cases, while in mucous melanomas, appeared
in 42.33% of cases, with melanoma of the oral cavity presenting the highest frequency—
80.05% of cases. It is interesting to note that also in the most frequent tumor of the oral
cavity, the oral squamous cell carcinoma, cyclin D1 is frequently overexpressed which has a
strong impact on the patients prognosis [19,52]. Although our meta-analysis in oral mucosa
melanomas is based on a small number of studies, these results justify more experimental
studies that increase the scientific evidence on the frequency of alterations of CCND1/cyclin
D1 and that ratify its prognostic implications in these type of melanomas. The results
indicate that the positive regulation of this gene and its protein, which are key to promot-
ing the progression of the cell cycle, is a oncogenic mechanism probably involved in the
malignant transformation of melanocytic cells, justifying its frequent presentation by the
number of oncogenic aberrations—gene amplification, mutations, polymorphisms, chro-
mosomal translocations—and molecular pathways that conclude with the upregulation of
CCND1/cyclin D1 in melanomas [22]; however, this upregulation, although frequent, was
not different in the different types of cutaneous melanomas. Among the latter, in recent
years, upregulation of CCND1/cyclin D1 dependent on activation of the MAPK pathway
(Ras/Raf/MEK/Erk) has been reported, with the MAPK pathway constitutive activation
being observed in 90% of melanomas [53], in which the BRaf and NRas mutations [54,55]
are especially important. Mechanisms of upregulation dependent on activation of the
PI3K/Akt pathway have also been reported, where mTor activates the mRNA CCND1
translation and promotes the formation of cyclin D1/CDK4 and CDK6 complexes, involved
in cell cycle progression [55]. Furthermore, CCND1/cyclin D1 upregulation mechanisms
linked to the failure of senescence associated with the actions of tumor suppressor gene
CDKN2A/p16INK4, mechanisms linked to alterations in growth receptors, mechanisms
linked to activation of the Wnt/βcatenin pathway, and mechanisms linked to epigenetic
regulations of CCND1/cyclin D1 have been also documented [22]. Usually, papers focusing
on CCND1/cyclin D1 upregulation do so by analyzing CCND1 gene amplification and/or
cyclin D1 immunohistochemical overexpression protein. Our results demonstrate a signifi-
cantly higher frequency of cyclin D1 immunohistochemical overexpression in melanomas
in comparison with the CCND1 gene amplification, which is probably related with the
multiple and frequent molecular pathways, previously discussed, that lead to upregulate
CCND1/cyclin D1 activity in the absence of gene amplification. In our meta-analysis,
CCND1 amplification was most frequently upregulated in acral melanomas (25.06%, 95%
CI = 15.80–35.44; out of 85 cases) than in other cutaneous melanomas subtypes. A recently
published integrative analysis from the “Pan-Cancer Analysis of Whole Genomes” of
the Consortium of the International Cancer Genome Consortium (ICGC) reported chro-
mothripsis involving CCND1 on chromosome 11 [56]. This alteration was also frequently
observed in 11/21 acral melanomas (52.38% of cases), and in 10/86 cutaneous melanomas
(11.63% of cases), most of which harboring gene amplifications [56]. Therefore, CCND1
focal amplification could be considered as a potential driver in the context of chromoth-
ripsis in acral melanomas. The Cancer Genome Atlas (TCGA) also confirmed variations
in copy-number gains across melanoma subtypes. CCND1 amplification was also deter-
mined as one of the most relevant copy-number alterations in Triple-WT subtype (11% of
cases were focally amplified), with a statistically significant increase (Fisher’s exact test:
p < 0.01) compared to BRAF (3%, out of 150 cases), RAS (8%, out of 92 cases), and NF1
(0%, out of 58 cases) [57]. Future somatic copy number alteration bioinformatics analyses
are needed in melanomas in order to comprehensively describe the genomic aberrations
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located in 11q13 chromosomal band—and singularly CCND1 amplification—from large-
scale sequencing-based datasets (e.g., TCGA and ICGC projects). In relation to cyclin D1
overexpression, whose relative frequency was more common, our results are relevant since
the immunohistochemistry is a simple, inexpensive, and commonly used technique in
pathology laboratories, which facilitates and probably advises its routine incorporation into
the melanoma diagnostic process. This meta-analysis has also revealed that the true value
of immunohistochemistry is obtained when the nuclear protein expression is considered
(p < 0.01; OR = 0.56, 95% CI = 0.41–0.76). Only one study has evaluated both the nuclear
and cytoplasmic expression of cyclin D1 in melanomas, so it has not been possible to obtain
data to meta-analyze; however, our research group has recently reported in oral squamous
cell carcinoma [58], the association of cytoplasmic cyclin D1 overexpression with the devel-
opment of actin-based protrusive structures—invadopodia and lamellipodia—in tumor
cells, which functions are related with the acquisition of invasive advantages of malignant
cells. In our opinion, it is advisable to expand the knowledge about the meaning and true
value of immunolocalization of cyclin D1 in the cytoplasm in melanoma. The frequent
CCND1/cyclin D1 upregulation in melanomas has stimulated the research of cyclin D1
inhibitors as a therapeutic tool [59]. Cyclin D1 complies with the concept of oncogenic
addiction described by Weinstein and Joe [60]—i.e., dependency of carcinogenic cells on
the expression of some oncoproteins, which allows them to survive and maintain their
proliferation—which implies that the therapeutic blockage of a single protein could have
benefits in the treatment of the tumor. Accordingly, cyclin D1 is a candidate protein that
can be targeted in different ways: by inhibition of chromosome band 11q13 and/or CCND1;
by direct cyclin D1 inhibition; by CDK inhibition, acting upstream on melanoma-related
pathways that involve cyclin D1; or by combining agents that act against cyclin D1 with
other antitumor drugs. There are reports on several drugs that inhibit these pathways
being tested in melanoma (it is advisable to consult Table 1 of [22]).
Our meta-analysis demonstrates associations between CCND1/cyclin D1 upregula-
tion and some clinicopathological features of melanoma, although no value has been shown
in predicting patient survival. Among them, stands out the significant association found be-
tween CCND1/cyclin D1 upregulation and Breslow thickness (p = 0.02) revealed essentially
through immunohistochemical overexpression of the protein (p = 0.007; OR = 2.09, 95%
CI = 1.23–3.57), while the CCND1 gene amplification does not show association (p = 0.43).
This observation could be explained, as mentioned above, by the multiple active onco-
genic pathways in melanoma that converge in CCND1/cyclin D1 upregulation without
genetic amplification. Likewise, a significantly higher frequency of CCND1/cyclin D1
abnormalities has been observed in the primary tumor compared to distant metastases
(p = 0.004), revealed also by immunohistochemical overexpression of the protein (p < 0.001;
OR = 0.53, 95% CI = 0.40–0.71), while gene amplification, on the contrary, appeared more
frequently in distant metastases (p = 0.04; OR = 1.70, 95% CI = 1.01–2.85) and not in the
primary tumor, which could be indicating gene amplifications as late events in melanocytic
oncogenesis probably linked to a phenomenon of genomic instability in highly proliferative
cell clones. This observed event could also be explained by the previously commented
chromothripsis on chromosome 11 associated to CCND1. These alterations seem to be
early events in the development of acral melanomas, but perhaps could be late events in
cutaneous melanomas, so the timing of amplification events could be different between
cutaneous and acral melanomas. On the other hand, cyclin D1 overexpression could be
an early event not associated to gene amplification as occurring in other cancers [19]. If
confirmed in future studies, cyclin D1 overexpression could be an early event in melanomas
due to the activation of oncogenic aberrant upstream pathways (e.g., MAPK, PI3K, and/or
WNT canonical) [6,22]. Taken together—greater expression in primary tumor vs. dis-
tant metastases and association with Breslow thickness—these data seem to indicate that
CCND1/cyclin D1 upregulation is especially influential in the local growth and expansion
of the tumor. On the other hand, the significantly lower frequency of cyclin D1 overexpres-
sion in distant metastases compared to the primary tumor is probably revealing its less
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important role in the development of the metastatic process, which could explain its lack of
value as a predictor of survival in melanomas, since distant metastases are the main cause
of death in this tumor.
According to our qualitative evaluation, carried out using the Quality in Prognosis
Studies (QUIPS) tool of the Cochrane Prognosis Methods Group [38], all studies were not
conducted with the same rigor. The domain “study confounding” harbored the highest risk
of potential bias, caused by the failure considering or measuring confounding factors. Fu-
ture studies assessing the prognostic and clinicopathological significance of CCND1/cyclin
D1 in melanomas should consider the potential biases reported in the present systematic
review and meta-analysis, using the QUIPS tool to improve the validity of findings and
facilitating comparisons.
Some potential limitations of our meta-analysis should be discussed. First, the restric-
tion to studies published in English may imply a loss of information published in other
languages, which would have been missed. Second, consistent heterogeneity was observed
in some variables (mainly in meta-analyses of proportions). In order to overcome this
limitation, a random-effect statistical model was applied in these meta-analyses. We also
conducted several secondary stratified analyses, obtaining more homogeneous subgroups
of studies. One potential source of methodological and statistical heterogeneity was the
combination CCND1 amplification and cyclin D1 overexpression at protein level (assessed
using immunohistochemistry), as observed after several stratifications. In general, the
amplification-based meta-analyses seem less significant in many-analyses and the reason
for this phenomenon could be due to various explanations among which are the following:
CCND1 amplification was not evaluated homogeneously across the studies, so a hetero-
geneity extent could be due to the inherent differences of the wide range of experimental
methods; Primary-level studies also presented differences in their statistical study designs,
and some considered the number of copies as a continuous variable (i.e., means of copies
with standard deviations), so when papers did not openly report individual patient data,
those reporting continuous variables had to be excluded under the “lack of essential data”
criterion, since in our meta-analysis, we estimated effect sizes for categorical variables
(i.e., odds ratios, hazard ratios, and pooled proportions); Finally, the non-significant re-
sults in amplification-based meta-analyses could also be due to the low sample sizes of
some included cohorts, with statistical analyses in underpowered conditions, yielding
non-significant results mainly due to type II errors (i.e., false negative results), so, another
important recommendation of the present work is the development of future better de-
signed studies—preferably prospective cohorts—assessing CCND1 amplification on higher
sample sizes. Another relevant recommendation, as previously commented, is the necessity
of future integrative bioinformatics analyses in melanomas in order to comprehensively de-
scribe the somatic copy number alteration linked to 11q13/CCND1 from massive datasets
(e.g., TCGA, ICGC projects, or from Gene Expression Omnibus (GEO). Specific bioinfor-
matics study design could better respond to additional research questions that could not be
addressed in this meta-analysis design (e.g., relationships between CCND1 amplification
and CCND1 RNA expression). Third, some variables (e.g., mitotic rate or ulceration) were
reported by a low number of studies and their meta-analyses were probably underpowered
to detect significant differences. Future studies should further elucidate the potential
influence of CCND1/cyclin D1 on these parameters. Finally, some studies reported a low
amount of data (e.g., anti-cyclin D1 antibody or cutoff points), limiting additional analyses.
The lack of essential information in the survival analysis (i.e., HR or 95% CI) was countered
estimating HR from the data provided by these studies, following the methodology of
Tierney et al. [41] and Parmar et al. [40]. Despite the above limitations, the results of our
meta-analysis are robust, as demonstrated by sensitivity and small-study effects analyses,
and as depicted in forest plots.
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6. Conclusions
In conclusion, CCND1/cyclin D1 upregulation is a common molecular oncogenic
alteration in melanomas that probably favors the growth and expansion of the primary
tumor. This upregulation is mainly a consequence to the overexpression of the cyclin
D1 protein, and not to gene amplification, which probably suggests the inclusion of the
immunohistochemical expression of cyclin D1 in the global evaluation of melanomas, and
opens the possibility of its use as a therapeutic target.
Supplementary Materials: The following are available online at https://www.mdpi.com/2072-6
694/13/6/1314/s1, Table S1. Search strategy for each database, number of results, and execution
date; Table S2. Characteristics of studies; Table S3. Sensitivity analysis of the studies pooled in
the meta-analysis on the association between CCND1/cyclin D1 alterations and overall survival in
cutaneous melanoma; Table S4. Sensitivity analysis of the studies pooled in the meta-analysis on the
association between CCND1/cyclin D1 alterations and Breslow Thickness in cutaneous melanoma;
Table S5. Sensitivity analysis of the studies pooled in the meta-analysis on the association between
CCND1/cyclin D1 alterations and Ulceration in cutaneous melanoma; Table S6. Sensitivity analysis
of the studies pooled in the meta-analysis on the association between CCND1/cyclin D1 alterations
and Clark in cutaneous melanoma; Table S7. Sensitivity analysis of the studies pooled in the meta-
analysis on the association between CCND1/cyclin D1 alterations and Type of cutaneous melanoma;
Table S8. Sensitivity analysis of the studies pooled in the meta-analysis on the association between
CCND1/cyclin D1 alterations and Distance metastasis vs primary in cutaneous melanoma; List of
studies included in this systematic review and meta-analysis; and copy of protocol. Figure S1. Forest
plot graphically representing the frequency of CCND1/cyclin D1 alterations in Nodular Melanomas;
Figure S2. Forest plot graphically representing the frequency of CCND1/cyclin D1 alterations in
Superficial Spreading Melanomas; Figure S3. Forest plot graphically representing the frequency of
CCND1/cyclin D1 alterations in Lentigo Malignant Melanomas; Figure S4. Forest plot graphically
representing the frequency of CCND1/cyclin D1 alterations in Acral Melanomas; Figure S5. Forest
plot graphically representing the association between CCND1/cyclin D1 alterations and Overall
Survival in Cutaneous Melanomas; Figure S6. Forest plot graphically representing the association
between CCND1/cyclin D1 alterations and Overall Survival in Cutaneous Melanomas by geographic
area; Figure S7. Forest plot graphically representing the association between CCND1/cyclin D1
alterations and Overall Survival in Cutaneous Melanomas by immunohistochemical pattern; Fig-
ure S8. Forest plot graphically representing the association between CCND1/cyclin D1 alterations
and Disease-Free Survival in Cutaneous Melanomas; Figure S9. Forest plot graphically represent-
ing the association between CCND1/cyclin D1 alterations and Breslow Thickness in Cutaneous
Melanomas by geographic area; Figure S10. Forest plot graphically representing the association
between CCND1/cyclin D1 alterations and Breslow Thickness in Cutaneous Melanomas by im-
munohistochemical pattern; Figure S11. Forest plot graphically representing the association between
CCND1/cyclin D1 alterations and Ulceration in Cutaneous Melanomas; Figure S12. Forest plot graph-
ically representing the association between CCND1/cyclin D1 alterations and N status in Cutaneous
Melanomas; Figure S13. Forest plot graphically representing the association between CCND1/cyclin
D1 alterations and M status in Cutaneous Melanomas; Figure S14. Forest plot graphically rep-
resenting the association between CCND1/cyclin D1 alterations and Clinical Stage in Cutaneous
Melanomas; Figure S15. Forest plot graphically representing the association between CCND1/cyclin
D1 alterations and Mitotic Rate in Cutaneous Melanomas; Figure S16. Forest plot graphically rep-
resenting the association between CCND1/cyclin D1 alterations and Clark levels in Cutaneous
Melanomas; Figure S17. Forest plot graphically representing the association between CCND1/cyclin
D1 alterations and types of melanoma (nodular vs. SSM/LMM/AM) in Cutaneous Melanomas;
Figure S18. Forest plot graphically representing the association between CCND1/cyclin D1 alterations
and types of melanoma (nodular vs. SSM/LMM/AM) in Cutaneous Melanomas by geographic
area; Figure S19. Forest plot graphically representing the association between CCND1/cyclin D1
alterations and types of melanoma (nodular vs. SSM/LMM/AM) in Cutaneous Melanomas by
immunohistochemical pattern; Figure S20. Forest plot graphically representing the association be-
tween CCND1/cyclin D1 alterations and tisular expression (Lymph node metastasis vs. primary
tissue) in Cutaneous Melanomas; Figure S21. Forest plot graphically representing the association
between CCND1/cyclin D1 alterations and tisular expression (distance metastasis vs. primary tissue)
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in Cutaneous Melanomas; Figure S22. Forest plot graphically representing the association between
CCND1/cyclin D1 alterations and tisular expression (distance metastasis vs. primary tissue) in
Cutaneous Melanomas by geographic area; Figure S23. Forest plot graphically representing the
association between CCND1/cyclin D1 alterations and tisular expression (distance metastasis vs.
primary tissue) in Cutaneous Melanomas by geographic area; Figure S24. Forest plot graphically
representing the frequency of CCND1/cyclin D1 alterations in Uveal Melanomas; Figure S25. Forest
plot graphically representing the association between CCND1/cyclin D1 alterations and Largest Basal
Dimension in Uveal Melanomas; Figure S26. Forest plot graphically representing the association
between CCND1/cyclin D1 alterations and pathology (epithelioid vs. spindle/mixed cell shape) in
Uveal Melanomas; Figure S27. Forest plot graphically representing the frequency of CCND1/cyclin
D1 alterations in Mucosal Melanomas; Figure S28. Forest plot graphically representing the frequency
of CCND1/cyclin D1 alterations in Mucosal Melanomas by anatomical site; Figure S29. Forest plot
graphically representing the association between CCND1/cyclin D1 alterations and Recurrence
in Mucosal Melanomas; Figure S30. Forest plot graphically representing the association between
CCND1/cyclin D1 alterations and Thickness in Mucosal Melanomas; Figure S31. Forest plot graphi-
cally representing the association between CCND1/cyclin D1 alterations and M status in Mucosal
Melanomas; Figure S32. Forest plot graphically representing the association between CCND1/cyclin
D1 alterations and Necrosis in Mucosal Melanomas; Figure S33. A funnel plot of estimated logHR
against its standard error, graphically representing the analysis of small-study effects on Overall
Survival in Cutaneous Melanomas; Figure S34. A funnel plot of estimated logOR against its standard
error, graphically representing the analysis of small-study effects on Distance Metastasis vs. Primary
tissue in Cutaneous Melanomas; Figure S35. A funnel plot of estimated logOR against its standard
error, graphically representing the analysis of small-study effects on Type of Cutaneous Melanomas;
Figure S36. A funnel plot of estimated logOR against its standard error, graphically representing the
analysis of small-study effects on Ulceration in Cutaneous Melanomas; Figure S37. A funnel plot
of estimated logOR against its standard error, graphically representing the analysis of small-study
effects on Ulceration in Cutaneous Melanomas.
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17. Lebe, B.; Pabuççuoğlu, U.; Ozer, E. The significance of Ki-67 proliferative index and cyclin D1 expression of dysplastic nevi in the
biologic spectrum of melanocytic lesions. Appl. Immunohistochem. Mol. Morphol. AIMM 2007, 15, 160–164. [CrossRef] [PubMed]
18. Miracco, C.; Pacenti, L.; Santopietro, R.; Biagioli, M.; Fimiani, M.; Perotti, R.; Rubegni, P.; Pirtoli, L.; Luzi, P. Detection of
telomerase activity and correlation with mitotic and apoptotic indices, Ki-67 and expression of cyclins D1 and A in cutaneous
melanoma. Int. J. Cancer 2000, 88, 411–416. [CrossRef]
19. Ramos-García, P.; Gil-Montoya, J.A.; Scully, C.; Ayén, A.; González-Ruiz, L.; Navarro-Triviño, F.J.; González-Moles, M.A. An
update on the implications of cyclin D1 in oral carcinogenesis. Oral Dis. 2017, 23. [CrossRef] [PubMed]
20. Wilkerson, P.M.; Reis-Filho, J.S. The 11q13-q14 amplicon: Clinicopathological correlations and potential drivers. Genes. Chromo-
somes Cancer 2013, 52, 333–355. [CrossRef] [PubMed]
21. Ramos-García, P.; Ruiz-Ávila, I.; Gil-Montoya, J.A.; Ayén, Á.; González-Ruiz, L.; Navarro-Triviño, F.J.; González-Moles, M.Á.
Relevance of chromosomal band 11q13 in oral carcinogenesis: An update of current knowledge. Oral Oncol. 2017, 72. [CrossRef]
[PubMed]
22. González-Ruiz, L.; González-Moles, M.A.; González-Ruiz, I.; Ruiz-Ávila, I.; Ayén, Á.; Ramos-García, P. An update on the
implications of cyclin D1 in melanomas. Pigment Cell Melanoma Res. 2020. [CrossRef] [PubMed]
23. Smalley, K.S.M.; Lioni, M.; Palma, M.D.; Xiao, M.; Desai, B.; Egyhazi, S.; Hansson, J.; Wu, H.; King, A.J.; Van Belle, P.; et al.
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol. Cancer Ther.
2008, 7, 2876–2883. [CrossRef] [PubMed]
24. Sauter, E.R.; Yeo, U.-C.; Von Stemm, A.; Zhu, W.; Litwiin, S.; Tichansky, D.S.; Pistritto, G.; Nesbit, M.; Pinkel, D.; Herlyn, M.; et al.
Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res. 2002, 62, 3200–3206.
25. Krayem, M.; Najem, A.; Journe, F.; Morandini, R.; Sales, F.; Awada, A.; Ghanem, G.E. Acquired resistance to BRAFi reverses
senescence-like phenotype in mutant BRAF melanoma. Oncotarget 2018, 9. [CrossRef] [PubMed]
26. Yoshida, A.; Lee, E.K.; Diehl, J.A. Induction of Therapeutic Senescence in Vemurafenib-Resistant Melanoma by Extended
Inhibition of CDK4/6. Cancer Res. 2016, 76, 2990–3002. [CrossRef]
27. Kiszner, G.; Wichmann, B.; Nemeth, I.B.; Varga, E.; Meggyeshazi, N.; Teleki, I.; Balla, P.; Maros, M.E.; Penksza, K.; Krenacs, T. Cell
cycle analysis can differentiate thin melanomas from dysplastic nevi and reveals accelerated replication in thick melanomas.
Virchows Arch. 2014, 464, 603–612. [CrossRef]
28. Weissinger, S.E.; Frick, M.; Möller, P.; Horst, B.A.; Lennerz, J.K. Performance Testing of RREB1, MYB, and CCND1 Fluorescence In
Situ Hybridization in Spindle-Cell and Desmoplastic Melanoma Argues for a Two-Step Test Algorithm. Int. J. Surg. Pathol. 2017,
25, 148–157. [CrossRef] [PubMed]
Cancers 2021, 13, 1314 20 of 21
29. Gammon, B.; Ali, L.; Guitart, J.; Gerami, P. Homogeneous staining regions for cyclin D1, a marker of poor prognosis in malignant
melanoma. Am. J. Dermatopathol. 2012, 34, 487–490. [CrossRef]
30. Kong, Y.; Sheng, X.; Wu, X.; Yan, J.; Ma, M.; Yu, J.; Si, L.; Chi, Z.; Cui, C.; Dai, J.; et al. Frequent genetic aberrations in the CDK4
pathway in acral melanoma indicate the potential for CDK4/6 inhibitors in targeted therapy. Clin. Cancer Res. 2017, 23, 6946–6957.
[CrossRef]
31. Bachmann, I.M.; Straume, O.; Akslen, L.A. Altered expression of cell cycle regulators Cyclin D1, p14, p16, CDK4 and Rb in
nodular melanomas. Int. J. Oncol. 2004, 25, 1559–1565. [CrossRef] [PubMed]
32. Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G. PRISMA Group Preferred reporting items for systematic reviews and meta-
analyses: The PRISMA statement. PLoS Med. 2009, 6, 1000097. [CrossRef] [PubMed]
33. Riley, R.D.; Ridley, G.; Williams, K.; Altman, D.G.; Hayden, J.; De Vet, H.C.W. Prognosis research: Toward evidence-based results
and a Cochrane methods group. J. Clin. Epidemiol. 2007, 60, 863–865. [CrossRef] [PubMed]
34. Higgins, J.P.; Green, S. Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series. Available online:
http://handbook.cochrane.org/ (accessed on 11 March 2021).
35. Centre for Reviews and Dissemination Group. Systematic Reviews: CRD’s Guidance for Undertaking Reviews in Health Care; York
Publishing Services Ltd.: York, UK, 2009.
36. Booth, A.; Clarke, M.; Dooley, G.; Ghersi, D.; Moher, D.; Petticrew, M.; Stewart, L. The nuts and bolts of PROSPERO: An
international prospective register of systematic reviews. Syst. Rev. 2012, 1, 2. [CrossRef] [PubMed]
37. Shamseer, L.; Moher, D.; Clarke, M.; Ghersi, D.; Liberati, A.; Petticrew, M.; Shekelle, P.; Stewart, L.A. PRISMA-P Group Preferred
reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: Elaboration and explanation. BMJ 2015,
350, 7647. [CrossRef]
38. Hayden, J.A.; Van der Windt, D.A.; Cartwright, J.L.; Côté, P.; Bombardier, C. Assessing bias in studies of prognostic factors. Ann.
Intern. Med. 2013, 158, 280–286. [CrossRef]
39. Hayden, J.A.; Côté, P.; Bombardier, C. Evaluation of the quality of prognosis studies in systematic reviews. Ann. Intern. Med.
2006, 144, 427–437. [CrossRef] [PubMed]
40. Parmar, M.K.; Torri, V.; Stewart, L. Extracting summary statistics to perform meta-analyses of the published literature for survival
endpoints. Stat. Med. 1998, 17, 2815–2834. [CrossRef]
41. Tierney, J.F.; Stewart, L.A.; Ghersi, D.; Burdett, S.; Sydes, M.R. Practical methods for incorporating summary time-to-event data
into meta-analysis. Trials 2007, 8, 16. [CrossRef] [PubMed]
42. Dekkers, O.M.; Vandenbroucke, J.P.; Cevallos, M.; Renehan, A.G.; Altman, D.G.; Egger, M. COSMOS-E: Guidance on conducting
systematic reviews and meta-analyses of observational studies of etiology. PLoS Med. 2019, 16, 1002742. [CrossRef] [PubMed]
43. Sweeting, M.J.; Sutton, A.J.; Lambert, P.C. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis
of sparse data. Stat. Med. 2004, 23, 1351–1375. [CrossRef] [PubMed]
44. Agresti, A.; Coull, B.A. Approximate is Better than “Exact” for Interval Estimation of Binomial Proportions. Am. Stat. 1998, 52,
119–126. [CrossRef]
45. Freeman, M.; Tuckey, J. Transformations Related to the Angular and the Square Root. Ann. Math. Stat. 1950, 21, 607–611.
[CrossRef]
46. Higgins, J.P.T.; Thompson, S.G. Quantifying heterogeneity in a meta-analysis. Stat. Med. 2002, 21, 1539–1558. [CrossRef]
[PubMed]
47. Higgins, J.P.T.; Thompson, S.G.; Deeks, J.J.; Altman, D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327, 557–560.
[CrossRef] [PubMed]
48. Viechtbauer, W.; Cheung, M.W.-L. Outlier and influence diagnostics for meta-analysis. Res. Synth. Methods 2010, 1, 112–125.
[CrossRef] [PubMed]
49. Egger, M.; Davey Smith, G.; Schneider, M.; Minder, C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315,
629–634. [CrossRef] [PubMed]
50. Sterne, J.A.C.; Sutton, A.J.; Ioannidis, J.P.A.; Terrin, N.; Jones, D.R.; Lau, J.; Carpenter, J.; Rücker, G.; Harbord, R.M.; Schmid, C.H.;
et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials.
BMJ 2011, 343, 4002. [CrossRef] [PubMed]
51. Chraybi, M.; Abd Alsamad, I.; Copie-Bergman, C.; Baia, M.; André, J.; Dumaz, N.; Ortonne, N. Oncogene abnormalities in a
series of primary melanomas of the sinonasal tract: NRAS mutations and cyclin D1 amplification are more frequent than KIT or
BRAF mutations. Hum. Pathol. 2013, 44, 1902–1911. [CrossRef]
52. Ramos-García, P.; González-Moles, M.; González-Ruiz, L.; Ruiz-Ávila, I.; Ayén, Á.; Gil-Montoya, J.A. Prognostic and clinicopatho-
logical significance of cyclin D1 expression in oral squamous cell carcinoma: A systematic review and meta-analysis. Oral Oncol.
2018, 83. [CrossRef] [PubMed]
53. Cohen, C.; Zavala-Pompa, A.; Sequeira, J.H.; Shoji, M.; Sexton, D.G.; Cotsonis, G.; Cerimele, F.; Govindarajan, B.; Macaron, N.;
Arbiser, J.L. Mitogen-actived protein kinase activation is an early event in melanoma progression. Clin. Cancer Res. 2002, 8,
3728–3733. [PubMed]
54. Bhatt, K.V.; Spofford, L.S.; Aram, G.; McMullen, M.; Pumiglia, K.; Aplin, A.E. Adhesion control of cyclin D1 and p27Kip1 levels is
deregulated in melanoma cells through BRAF-MEK-ERK signaling. Oncogene 2005, 24, 3459–3471. [CrossRef]
Cancers 2021, 13, 1314 21 of 21
55. Sekulic, A.; De Lamo, G.J.; Ejadi, S.; Pulido, J.S.; Diva, R.; Thorland, E.C.; Vile, R.G.; Swanson, D.L.; Pockaj, B.A.; Laman, S.D.; et al.
Malignant Melanoma in the 21st Century: The Emerging Molecular Landscape. Mayo Clin. Proc. 2009, 83, 825–846. [CrossRef]
[PubMed]
56. ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium Pan-cancer analysis of whole genomes. Nature 2020, 578,
82–93. [CrossRef]
57. Akbani, R.; Akdemir, K.C.; Aksoy, B.A.; Albert, M.; Ally, A.; Amin, S.B.; Arachchi, H.; Arora, A.; Auman, J.T.; Ayala, B.; et al.
Genomic Classification of Cutaneous Melanoma. Cell 2015, 161, 1681–1696. [CrossRef] [PubMed]
58. Ramos-García, P.; Bravo, M.; González-Ruiz, L.; González-Moles, M. Significance of cytoplasmic cyclin D1 expression in oral
oncogenesis. Oral Dis. 2018, 24, 98–102. [CrossRef] [PubMed]
59. Musgrove, E.A.; Caldon, C.E.; Barraclough, J.; Stone, A.; Sutherland, R.L. Cyclin D as a therapeutic target in cancer. Nat. Rev.
Cancer 2011, 11, 558–572. [CrossRef] [PubMed]
60. Weinstein, I.B.; Joe, A.K. Mechanisms of disease: Oncogene addiction–A rationale for molecular targeting in cancer therapy. Nat.
Clin. Pract. Oncol. 2006, 3, 448–457. [CrossRef] [PubMed]
